期刊文献+

血清胱氨酸蛋白酶抑制剂C在高血压患者肾功能早期损伤诊断中的应用价值 被引量:9

Application of cystatin C to diagnosis of early renal impairment in patients with hypertension
在线阅读 下载PDF
导出
摘要 目的探讨血清胱氨酸蛋白酶抑制剂C(胱抑素C)在诊断高血压患者肾功能早期损伤中的应用价值。方法将血清肌酐(Cr)和尿素氯(BUN)正常的645例患者,按尿微量蛋白(UMP)是否正常分为肾功能正常组(412例)和肾功能早期损伤组(233例);按患者血压状况将肾功能正常组又分为非高血压组(208例)和高血压组(204例),肾功能早期损伤组也分为非高血压组(109例)和高血压组(124例)。进行血清胱抑素C、UMP测定,并结合其血压进行分析。结果肾功能正常组中,高血压组患者的胱抑素C与非高血压组无显著性差异(P>0.05)。肾功能早期损伤组中,高血压组的胱抑素C值(1.06±0.23)mg/L比非高血压组高[(1.02±0.22)mg/L,P<0.05]。结论血清胱抑素C与UMP联合分析可以更有效地判断高血压是否对肾功能产生早期损伤。 Objective To evaluate the applicability of serum cystatin C to diagnosis of early renal impairment in patients with hypertension. Methods Serum cystatin C and urine microprotein (UMP) were measured in 645 patients with normal serum Cr and BUN. The data and the blood pressure of the patients were analysed together. The patients were divided into normal renal function group(412 cases) and early renal impairment group(233 cases) according to their UMP results. Based on their blood pressure, the patients in the normal renal function group were further divided into normal blood pressure group(208 cases) and hypertension group(204 cases),and the patients in the early renal impairment group were further divided into normal blood pressure group(109 cases) and hypertension group(124 cases). Results When the renal function had no distinguishable impairment,cystatin C had no significant statistical difference between the hypertension group and normal blood pressure group( P 〉0.05). When the renal function had early impairment,the mean of cystatin C in the group with hypertension[(1.06±0.23) mg/L)] was higher than that in the group with normal blood pressure[(1. 02±0. 22) mg/L, P %0. 05]. Conclusion Analysis of serum cystatin C and UMP together would be helpful to estimating the early renal impairment of patients with hypertension effectively.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2007年第11期730-732,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 高血压 肾病 尿素 半胱氨酸蛋白酶抑制剂 hypertension nephrosis urea cysteine proteinase inhibitors
  • 相关文献

参考文献9

  • 1Randers E, Erlandsen EJ. Serum cystatin C as endogenous marker of the renal function review[J]. Clin Chem Lab Med, 1999,37:389-395.
  • 2Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension[J]. J Hypertens, 1999,17:151-183.
  • 3Lue G, Bard JM, Lesueur C. Plasma eystatin-C and development of coronary heart disease: The PRIME Study[J]. Atherosclerosis, 2006,18 : 375-380.
  • 4Bokenkamp A, Herget-Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease[J]. Pediatr Nephrol,2006,21 : 1223-1230.
  • 5Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate[J]. Curr Opin Nephrol Hypertens, 2006,15: 610-616.
  • 6Segura J, Ruilope LM, Rodicio JL. Microalbuminuria[J]. Clin Exp Hypertens, 2004,26 :701-707.
  • 7Stare F, Guldener C, Schalkwijk CG, et al. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory aetivity[J]. Nephrol Dial Transplant, 2003,18 : 892-898.
  • 8Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography[J]. Nephrol Dial Transplant,2007,22: 295-296.
  • 9陈楠,陈佳韵.重视微量白蛋白尿的筛查与诊治[J].实用医院临床杂志,2005,2(1):17-19. 被引量:26

二级参考文献20

  • 1[1]Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002,39(2 Suppl 2) :S1~ 246.
  • 2[2]Parving HH, Mogensen CE,Jensen HA,et al.Increased urinary albumin-excretion rate in benign essential hypertension [J] .Lancet 1974, 1(7868):1190~2.
  • 3[3]Mogensen CE.Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes [J]. N Eng J Med, 1984,310(6): 356~60.
  • 4[4]Mogensen CE, Schmitz. The diabetic kidney: from hyerfitration and microalbuminura to end stage renal failure [J]. Med Clin North Am,1988, 72(6): 1465 ~ 92.
  • 5[5]Weir MR. Microalbuminuria in type 2 diabetes: an important, overlooked cardiovascular risk factor [J]. J Clin Hypertens, 2004,6 (3):134 ~ 41.
  • 6[6]Hillege HL, Fidler V, Diercks GF,et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population [J]. Circulation, 2002,106(14): 1777 ~ 82.
  • 7[7]Barzilay JI, Peterson D, et al.The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: The Cardiovascular Health Study [J] . Am J Kidney Dis, 2004,44: 25 ~ 34.
  • 8[8]Atkins RC, Polkinghorne KR, et al. Prevalence of albuminuria in Australia: The Ausdiab kidney study [J] .Kidney Int, 2004, 66(Suppl 92) :S22 ~ 4.
  • 9[9]Weir MR. Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia-Pacific Rim [J]. Kidney Int ( Suppl 92 ),2004,66:S38 ~ 9.
  • 10[10]Hillege HL, Jamssen WM, Bak AA, et al. Microalbuminuria is common,also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity[J].J Int Med,2001,249(6) :519 ~ 26.

共引文献25

同被引文献55

引证文献9

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部